1st Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$870,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan drug tax credit

LobbyistCovered position, as disclosed
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

LobbyistCovered position, as disclosed
ENGEL BURNS —
MARK LENKER —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration

LobbyistCovered position, as disclosed
ENGEL BURNS —
JED PERRY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6 (115th)

Pharmacy PHA

ADHD Awareness *Drug Values -Binge Eating Disorder awareness -DEA processes and re-exportation -FDA Funding -Medicaid rare disease patient access to therapy -Orphan drug tax credit -Orphan Drug Act regulations -HR 1628 - American Health Care Act of 2017 -PDUFA Reauthorization

LobbyistCovered position, as disclosed
MARK LENKER —
JED PERRY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1628 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.